NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$25.21
-1.51 (-5.65%)
Close of Nov 06, 2026 · end-of-day data
STAA 8-K filings in 2025
Every material Form 8-K STAAR Surgical filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
STAAR Surgical entered Amendment No. 2 to its merger agreement with Alcon Research, LLC and Rascasse Merger Sub, Inc. on December 9, 2025. The amendment raises the cash consideration for each STAAR common share to $30.75 from $28.00 if the merger is completed, and changes how certain equity awards and 280G tax gross-ups are handled.
Merger consideration increased to $30.75 per share in cash, without interest, from $28.00 per share
Amendment converts certain restricted stock units and performance-based awards into Alcon Inc. restricted stock units, with performance deemed earned at 100% of target
Amendment eliminates 280G gross-ups and related tax indemnification arrangements; director awards vest at closing
STAAR Surgical entered into an amendment to its merger agreement with Alcon that allows the company to actively solicit rival acquisition proposals through December 6, 2025. The company also postponed its stockholder vote on the Alcon merger to December 19, 2025, and the amendment sets the termination fee at $0 in certain superior-offer scenarios, which affects shareholders' choices in the pending deal.
Go-shop period runs from November 7, 2025 until 11:59 p.m. Eastern Time on December 6, 2025
Alcon waives matching rights for any superior offer; STAAR must give Alcon four business days' notice before terminating to accept one
Termination fee is $0 if STAAR terminates to accept a superior proposal from a Qualified Bidder, or in certain circumstances where a deal is signed within 12 months
Special meeting to vote on the Alcon merger moved from December 3, 2025 to December 19, 2025 at 8:30 a.m. Pacific Time; record date remains October 24, 2025
STAAR Surgical reported third quarter 2025 results for the period ended September 26, 2025. Net sales rose 6.9% from a year earlier to $94.7 million, helped by $25.9 million from a December 2024 China shipment that was paid in full this quarter, while net income fell to $8.9 million, or $0.18 per diluted share, from $10.0 million, or $0.20 per share. Because the company is being acquired by Alcon Inc., it will not hold a conference call on the results.
Net sales were $94.7 million, up 6.9% from $88.6 million a year earlier, including $25.9 million from the December China Shipment.
Net sales excluding China were $38.9 million, up 7.7% year over year.
Net income was $8.9 million, or $0.18 per diluted share, versus $10.0 million, or $0.20 per share, a year earlier; the company recorded $5.9 million in merger transaction costs.
Adjusted EBITDA was $34.6 million, or $0.68 per share, compared with $16.2 million, or $0.33 per share, a year earlier.
STAAR Surgical released preliminary third-quarter 2025 net sales of $94.7 million, up 6.9% from $88.6 million a year earlier, ahead of its October 23, 2025 stockholder vote on the Alcon merger proposal. The increase relied heavily on a $25.9 million December 2024 China shipment paid in full in the quarter, while distributor orders in China fell and nine-month sales declined year over year. The figures are unaudited and subject to change before the 10-Q is filed.
Q3 2025 preliminary net sales of $94.7 million, up 6.9% from $88.6 million
$25.9 million from the December 2024 China shipment was recognized in Q3 2025 after payment in full
Net sales outside China grew 7.7%, while new orders from China distributors were lower
Nine-month 2025 sales were lower than the prior year, as China distributors reduced inventory by about $80 million to $85 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every STAAR Surgical filing is on SEC EDGAR ↗. 8-K briefs of other companies →